Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Sponsor: Exelixis
Terminated
Business reasons
Other terminated trials from Exelixis
Other Epithelial Ovarian Cancer trials with similar outcome
This PHASE1 trial investigates Epithelial Ovarian Cancer and Hormone Receptor Positive Breast Carcinoma and is currently terminated or withdrawn. Exelixis leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Mar 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
May 2022 — Oct 2023 [monthly]
Recruiting PHASE1
-
Sep 2021 — May 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Exelixis
For direct contact, visit the study record on ClinicalTrials.gov .